Compare BZAI & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZAI | LUCD |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | 254 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.9M | 190.8M |
| IPO Year | N/A | 2021 |
| Metric | BZAI | LUCD |
|---|---|---|
| Price | $1.77 | $1.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.50 | $4.13 |
| AVG Volume (30 Days) | ★ 7.3M | 521.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | $239.02 | $126.14 |
| Revenue Next Year | $46.03 | $138.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $1.00 | $0.95 |
| 52 Week High | $6.76 | $1.70 |
| Indicator | BZAI | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 63.83 |
| Support Level | $1.03 | $1.01 |
| Resistance Level | $2.40 | $1.52 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 47.49 | 83.33 |
Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.